PATRYS Ltd (PAB) - Total Liabilities
Based on the latest financial reports, PATRYS Ltd (PAB) has total liabilities worth AU$1.01 Million AUD (≈ $711.96K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PATRYS Ltd - Total Liabilities Trend (2007–2025)
This chart illustrates how PATRYS Ltd's total liabilities have evolved over time, based on quarterly financial data. See PATRYS Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
PATRYS Ltd Competitors by Total Liabilities
The table below lists competitors of PATRYS Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sejin T.S Co.Ltd
KQ:067770
|
Korea | ₩1.08 Billion |
|
Sama Resources Inc.
V:SME
|
Canada | CA$63.28K |
|
Adaptimmune Therapeutics Plc
NASDAQ:ADAP
|
USA | $201.59 Million |
|
Kim Hin Joo
KLSE:0210
|
Malaysia | RM23.55 Million |
|
Jatcorp Ltd
AU:JAT
|
Australia | AU$18.64 Million |
|
Rubicon Water Ltd
AU:RWL
|
Australia | AU$44.07 Million |
|
Metalsgrove Mining Ltd
AU:MGA
|
Australia | AU$123.69K |
|
REMAK SA
WAR:RMK
|
Poland | zł94.32 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down PATRYS Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PATRYS Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.74 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PATRYS Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PATRYS Ltd (2007–2025)
The table below shows the annual total liabilities of PATRYS Ltd from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.01 Million ≈ $711.96K |
+45.54% |
| 2024-06-30 | AU$691.37K ≈ $489.18K |
+0.65% |
| 2023-06-30 | AU$686.90K ≈ $486.02K |
+26.54% |
| 2022-06-30 | AU$542.83K ≈ $384.08K |
-36.13% |
| 2021-06-30 | AU$849.86K ≈ $601.33K |
+70.52% |
| 2020-06-30 | AU$498.38K ≈ $352.64K |
-21.81% |
| 2019-06-30 | AU$637.42K ≈ $451.02K |
-6.50% |
| 2018-06-30 | AU$681.77K ≈ $482.40K |
+37.58% |
| 2017-06-30 | AU$495.53K ≈ $350.62K |
-20.11% |
| 2016-06-30 | AU$620.26K ≈ $438.87K |
-22.69% |
| 2015-06-30 | AU$802.28K ≈ $567.67K |
-66.28% |
| 2014-06-30 | AU$2.38 Million ≈ $1.68 Million |
+120.06% |
| 2013-06-30 | AU$1.08 Million ≈ $765.05K |
+17.99% |
| 2012-06-30 | AU$916.36K ≈ $648.38K |
-33.63% |
| 2011-06-30 | AU$1.38 Million ≈ $976.96K |
+28.55% |
| 2010-06-30 | AU$1.07 Million ≈ $760.00K |
-26.41% |
| 2009-06-30 | AU$1.46 Million ≈ $1.03 Million |
+65.44% |
| 2008-06-30 | AU$882.30K ≈ $624.28K |
-62.55% |
| 2007-06-30 | AU$2.36 Million ≈ $1.67 Million |
-- |
About PATRYS Ltd
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated wit… Read more